sur Jaguar Health, Inc. (NASDAQ:JAGX)
Magdalena Biosciences Set to Present at Neuroscience Innovation Forum
Magdalena Biosciences, a joint initiative by Jaguar Health and Filament Health, will present at the Annual Neuroscience Innovation Forum in San Francisco on January 12, 2025. Dr. Karen Brunke, acting CEO of Magdalena, will discuss their botanical drug candidate, MB2500. The company plans to submit an Investigational New Drug (IND) application to the FDA in 2025, targeting mental health conditions like ADHD and schizophrenia.
MB2500 stands out due to its derivation from a plant used traditionally for its neuroprotective properties. It aims to address cognitive deficits in schizophrenia, a significant unmet medical need. With the global ADHD market estimated at $25 billion, Magdalena seeks to innovate in a sector demanding safer treatments.
The venture represents a shift in drug development, leveraging traditional plant-based medicines to quickly reach clinical studies. Magdalena plans additional IND-enabled applications in 2025, aiming for significant advancements in psychoactive plant-based therapies.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.